Johnson & Johnson (JNJ) has been a relative underperformer within the Drug sector, which is currently one of the weakest sectors in the SIA matrix, showing low relative strength. With the sector’s continued weakness, JNJ shares may complete a quadruple bottom sell signal if they slip below $139.39, while resistance remains tight at higher levels around $163 and $169.